EVENTS | VIEW CALENDAR
Bringing MRIs to the bedside
GUILFORD, Conn.—Hyperfine Research, Inc. announced today that it has received U.S. Food & Drug Administration (FDA) 510(k) clearance for the world’s first bedside Magnetic Resonance Imaging (MRI) system. The company notes that this clearance paves the way for device shipments this summer.
“Nearly six years ago, a dream to create a portable, affordable MRI system was born,” said Jonathan Rothberg, Ph.D., founder and chairman of Hyperfine Research. “We assembled an astounding team, and they took the 10 million-fold improvement in computing power since MRI was invented and the best of the billions invested in green electronics and built something astonishing, something disruptive.”
The Hyperfine system was designed to address the limitations of current MRI systems in order to make MRI accessible anytime, anywhere, to any patient. The device represents multiple innovations in MRI design, architecture and workflow. More than 100 patents have been issued or are currently pending. The system is highly portable and wheels directly to the patient’s bedside, plugs into a standard electrical wall outlet and is controlled via a wireless tablet such as an Apple iPad. The Hyperfine system is 20 times lower in cost, 35 times lower in power consumption and 10 times lower in weight than a fixed conventional MRI system.
“More than 40 years after its first use, MRI remains a marvel. Unfortunately, it also remains inaccessible. It’s time that MRI made the jump to point of need just like X-ray and ultrasound have before it,” noted Dr. Khan Siddiqui, Hyperfine’s chief medical officer. “Going beyond that, nearly 90% of the world has no access to MRI at all. With the FDA’s decision, we are now ready to rewrite the rules of MRI accessibility.”
While developing the system, Hyperfine performed thousands of brain scans — including those within investigational partnerships at Yale New Haven University, Penn Medicine, Good Samaritan Hospital Long Island, New York Presbyterian Brooklyn Methodist Hospital and Brown University — in addition to calling upon seminal work from the Martinos Center for Biomedical Imaging at Massachusetts General Hospital. The FDA clearance includes head imaging for patients aged 2 years and older.
Hyperfine will be demonstrating the new bedside MRI system at the International Stroke Conference in Los Angeles, CA, from February 19-21; the NVIDIA GPU Technology Conference in San Jose, CA, from March 23-26; and, the American Society of Neuroradiology in Las Vegas, NV, from May 30 – June 4, 2020.